Taysha Gene Therapies/$TSHA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Taysha Gene Therapies
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Ticker
$TSHA
Sector
Primary listing
Employees
73
Headquarters
Website
TSHA Metrics
BasicAdvanced
$791M
-
-$0.34
0.96
-
Price and volume
Market cap
$791M
Beta
0.96
52-week high
$3.40
52-week low
$1.05
Average daily volume
3.3M
Financial strength
Current ratio
12.476
Quick ratio
12.338
Long term debt to equity
23.329
Total debt to equity
23.262
Interest coverage (TTM)
-1,087.39%
Profitability
EBITDA (TTM)
-88.008
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,144.97%
Operating margin (TTM)
-1,101.09%
Revenue per employee (TTM)
$110,000
Management effectiveness
Return on assets (TTM)
-20.88%
Return on equity (TTM)
-51.86%
Valuation
Price to revenue (TTM)
98.834
Price to book
3.18
Price to tangible book (TTM)
3.18
Price to free cash flow (TTM)
-9.697
Free cash flow yield (TTM)
-10.31%
Free cash flow per share (TTM)
-0.299
Growth
Revenue change (TTM)
-37.09%
Earnings per share change (TTM)
-41.15%
3-year earnings per share growth (CAGR)
-58.84%
What the Analysts think about TSHA
Analyst ratings (Buy, Hold, Sell) for Taysha Gene Therapies stock.
Bulls say / Bears say
Taysha has obtained written agreement from the FDA on the design of the pivotal Part B REVEAL trial and can submit the trial protocol and statistical plan as an IND amendment—potentially accelerating study start and registration by skipping a formal end-of-phase meeting.
Both high and low doses of TSHA-102 have shown a positive safety profile so far, with no treatment-related serious adverse events or dose-limiting toxicities in pediatric, adolescent, and adult participants across REVEAL Phase 1/2 trials.
Results from REVEAL Part A demonstrated a 100% responder rate for the primary endpoint—gaining or regaining at least one developmental milestone—supporting TSHA-102’s potential therapeutic benefit in treating Rett syndrome.
Taysha’s entire pipeline depends on a single clinical-stage asset, TSHA-102. If this program fails or is delayed, the company’s business would be significantly affected since there are no alternative late-stage candidates.
Efficacy and safety results are drawn from a very small cohort of 10 patients in REVEAL Part A, so these preliminary findings have a high risk of failure or may not be reproducible in larger pivotal trials.
Gene therapy development for the central nervous system (CNS) is typically very costly and time-consuming. Taysha may need significant additional funding, raising the risk of shareholder dilution if clinical or regulatory milestones are delayed beyond its current cash reserves.
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
TSHA Financial Performance
Revenues and expenses
TSHA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Taysha Gene Therapies stock?
Taysha Gene Therapies (TSHA) has a market cap of $791M as of September 18, 2025.
What is the P/E ratio for Taysha Gene Therapies stock?
The price to earnings (P/E) ratio for Taysha Gene Therapies (TSHA) stock is 0 as of September 18, 2025.
Does Taysha Gene Therapies stock pay dividends?
No, Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Taysha Gene Therapies dividend payment date?
Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.